Guillermo Moreno-Sanz

Title: Guillermo Moreno-Sanz: Innovator in Peripheral FAAH Inhibition

Introduction

Guillermo Moreno-Sanz is a notable inventor based in Irvine, California. He has made significant contributions to the field of pharmacology, particularly in the development of inhibitors for fatty acid amide hydrolase (FAAH). With two patents to his name, his work focuses on addressing various medical conditions through innovative compounds.

Latest Patents

Moreno-Sanz's latest patents include "Meta-substituted biphenyl peripherally restricted FAAH inhibitors" and "Peripherally restricted FAAH inhibitors." The first patent outlines methods for creating and utilizing inhibitors that specifically target FAAH activity outside the central nervous system. This invention aims to increase anandamide levels, which can be beneficial in treating conditions such as pain, inflammation, and immune disorders. The second patent emphasizes the development of compounds that can suppress FAAH activity while demonstrating efficacy in rodent models of persistent pain, despite limited access to the brain and spinal cord.

Career Highlights

Throughout his career, Guillermo Moreno-Sanz has worked with prestigious institutions, including the University of California and Università degli Studi di Parma. His research has focused on the therapeutic potential of peripheral FAAH inhibition, contributing to advancements in pain management and related fields.

Collaborations

Moreno-Sanz has collaborated with esteemed colleagues such as Daniele Piomelli and Marco Mor. These partnerships have fostered a collaborative environment that enhances the research and development of innovative pharmacological solutions.

Conclusion

Guillermo Moreno-Sanz is a prominent figure in the field of pharmacology, with a focus on developing innovative FAAH inhibitors. His contributions have the potential to significantly impact the treatment of various medical conditions, showcasing the importance of innovation in healthcare.